06:24 AM EDT, 10/22/2025 (MT Newswires) -- Intuitive Surgical ( ISRG ) shares jumped early Wednesday as the robotic surgical systems company reported stronger-than-expected third-quarter results, driven by double-digit growth in procedure volumes.

Adjusted earnings came in at $2.40 a share for the September quarter, up from $1.84 the year before, the company said late Tuesday. The consensus on FactSet was for non-GAAP EPS of $1.99. Revenue climbed 23% to $2.51 billion, topping the Street's view of $2.41 billion.

"(The third quarter of 2025) was an excellent quarter for Intuitive, with strength and worldwide procedure growth and capital placements as well as increasing utilization across all platforms," Chief Executive David Rosa said during an earnings call, according to a FactSet transcript. The stock rose 16% in the most recent premarket activity.

Revenue in the instruments and accessories segment inclined 20% to $1.52 billion. The increase was mainly driven by roughly 19% growth in the number of procedures using the company's da Vinci robotic surgery systems and a 52% surge in Ion procedure volume, according to the firm. Procedures in the US rose 18% and gained 25% outside the country, Chief Financial Officer Jamie Samath said on the call.

Systems revenue amounted to $590.4 million, up from $445 million a year ago. The firm placed 427 da Vinci surgical systems during the quarter, including 240 da Vinci 5 systems, versus 379 last year. Services revenue moved up to $395.9 million from $328.9 million.

For full-year 2025, Intuitive Surgical ( ISRG ) now expects adjusted gross profit margin to be in a range of 67% to 67.5% of revenue, up from the previous outlook of 66% to 67%. The latest guidance includes a tariff headwind of 0.7% of revenue, plus or minus 10 basis points, compared with the prior forecast for an impact of 1% of revenue, plus or minus 20 basis points.

"Given (third quarter) results, which reflected greater leverage of fixed costs and benefits from cost reductions, as well as a lower expected tariff impact for the year, we are updating our estimate of pro forma gross margin," Dan Connally, head of investor relations, said on the call.

The company now expects worldwide da Vinci procedure growth of 17% and 17.5% for the current year, up from its previous guidance for a 15.5% to 17% increase.